Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Mohamed A. El-Shahawy, MD, MPH, MHA, FASN, CPI
Director and Principal Investigator
Clinical Professor of Medicine (Adjunct), Keck School of Medicine of USC
Trial Overview
This protocol medication aims at slowing the progression of renal cyst growth with the aim of delaying the decline in kidney function in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Key Inclusion Criteria
- Diagnosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Age: 18 to 55 years old
- Kidney function: eGFR ≥ 30 mL/min, and < 90 mL/min
Why Join This Clinical Trial?
– Access to highly experienced Board certified Nephrologists
– Participation is voluntary, and you will learn all details about the protocol by Contacting with our clinical team contact us.
– Clinical trials offer additional care options for your condition, with access to new medicines at no cost.
– Help move science forward and improve human health, wellbeing, and quality of life.
– No cost to participate.
Compensation
– The range of payment for each visit ranges from $50 to $200.
– Total amount of compensation if all scheduled protocol visits are completed would be $4,200.
– Free Transportation will be provided
Connect with Our Clinical Team
